206 related articles for article (PubMed ID: 34865476)
1. Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies.
Dampalla CS; Rathnayake AD; Perera KD; Jesri AM; Nguyen HN; Miller MJ; Thurman HA; Zheng J; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Kim Y; Groutas WC; Chang KO
J Med Chem; 2021 Dec; 64(24):17846-17865. PubMed ID: 34865476
[TBL] [Abstract][Full Text] [Related]
2. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
[TBL] [Abstract][Full Text] [Related]
4. Improved SARS-CoV-2 M
Vuong W; Fischer C; Khan MB; van Belkum MJ; Lamer T; Willoughby KD; Lu J; Arutyunova E; Joyce MA; Saffran HA; Shields JA; Young HS; Nieman JA; Tyrrell DL; Lemieux MJ; Vederas JC
Eur J Med Chem; 2021 Oct; 222():113584. PubMed ID: 34118724
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
[TBL] [Abstract][Full Text] [Related]
6. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
[TBL] [Abstract][Full Text] [Related]
7. Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2.
Welker A; Kersten C; Müller C; Madhugiri R; Zimmer C; Müller P; Zimmermann R; Hammerschmidt S; Maus H; Ziebuhr J; Sotriffer C; Schirmeister T
ChemMedChem; 2021 Jan; 16(2):340-354. PubMed ID: 32930481
[TBL] [Abstract][Full Text] [Related]
8. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
[TBL] [Abstract][Full Text] [Related]
9. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.
Drayman N; DeMarco JK; Jones KA; Azizi SA; Froggatt HM; Tan K; Maltseva NI; Chen S; Nicolaescu V; Dvorkin S; Furlong K; Kathayat RS; Firpo MR; Mastrodomenico V; Bruce EA; Schmidt MM; Jedrzejczak R; Muñoz-Alía MÁ; Schuster B; Nair V; Han KY; O'Brien A; Tomatsidou A; Meyer B; Vignuzzi M; Missiakas D; Botten JW; Brooke CB; Lee H; Baker SC; Mounce BC; Heaton NS; Severson WE; Palmer KE; Dickinson BC; Joachimiak A; Randall G; Tay S
Science; 2021 Aug; 373(6557):931-936. PubMed ID: 34285133
[TBL] [Abstract][Full Text] [Related]
10. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
[TBL] [Abstract][Full Text] [Related]
12. All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity.
Morita T; Miyakawa K; Jeremiah SS; Yamaoka Y; Sada M; Kuniyoshi T; Yang J; Kimura H; Ryo A
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452533
[TBL] [Abstract][Full Text] [Related]
13. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
[TBL] [Abstract][Full Text] [Related]
14. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
[TBL] [Abstract][Full Text] [Related]
15. Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed
Morris A; McCorkindale W; Consortium TCM; Drayman N; Chodera JD; Tay S; London N; Lee AA
Chem Commun (Camb); 2021 Jun; 57(48):5909-5912. PubMed ID: 34008627
[TBL] [Abstract][Full Text] [Related]
16. A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.
Vankadara S; Wong YX; Liu B; See YY; Tan LH; Tan QW; Wang G; Karuna R; Guo X; Tan ST; Fong JY; Joy J; Chia CSB
Bioorg Med Chem Lett; 2021 Sep; 48():128263. PubMed ID: 34271072
[TBL] [Abstract][Full Text] [Related]
17. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
18. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.
Luttens A; Gullberg H; Abdurakhmanov E; Vo DD; Akaberi D; Talibov VO; Nekhotiaeva N; Vangeel L; De Jonghe S; Jochmans D; Krambrich J; Tas A; Lundgren B; Gravenfors Y; Craig AJ; Atilaw Y; Sandström A; Moodie LWK; Lundkvist Å; van Hemert MJ; Neyts J; Lennerstrand J; Kihlberg J; Sandberg K; Danielson UH; Carlsson J
J Am Chem Soc; 2022 Feb; 144(7):2905-2920. PubMed ID: 35142215
[TBL] [Abstract][Full Text] [Related]
19. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A
J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
